Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139932 | 1.00 | TRPM8 (0.34) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL18180584 | 0.86 | HTT (0.33) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL15889422 | 0.85 | — | — | |
| SCHEMBL14950801 | 0.85 | L3MBTL1 (0.33) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL18467490 | 0.85 | L3MBTL1 (0.33) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL14950802 | 0.85 | L3MBTL1 (0.33) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL18467489 | 0.85 | L3MBTL1 (0.33) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL18467491 | 0.85 | L3MBTL1 (0.33) | TRPM8SMYD3ALDH1A1L3MBTL1 | |
| SCHEMBL10210054 | 0.83 | TRPM8 (0.35) | TRPM8SMYD3L3MBTL1 | |
| SCHEMBL10210058 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | disclosed |
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-02 | — | — | US | disclosed |
| WO-2012021591-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011075439-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | TRPM8 4238/4885SMYD3 3660/4885ALDH1A1 1107/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | TRPM8 4303/4885SMYD3 3273/4885ALDH1A1 3778/4885 |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | TRPM8 4469/4885SMYD3 3771/4885ALDH1A1 2265/4885 |
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TRPM8 4212/4885SMYD3 3750/4885ALDH1A1 1144/4885 |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TRPM8 4212/4885SMYD3 3750/4885ALDH1A1 1144/4885 |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TRPM8 4212/4885SMYD3 3750/4885ALDH1A1 1144/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | TRPM8 4420/4885SMYD3 3084/4885ALDH1A1 1627/4885 |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TRPM8 4212/4885SMYD3 3750/4885ALDH1A1 1144/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TRPM8 4212/4885SMYD3 3750/4885ALDH1A1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.